Navidea Biopharmaceuticals, Inc. (NAVB)
USD 0.0
(100.0%)
USD 0.0
(100.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 4.37 Million USD | -34.21% |
| 2021 | 6.64 Million USD | -14.35% |
| 2020 | 7.75 Million USD | 86.9% |
| 2019 | 4.15 Million USD | -40.78% |
| 2018 | 7 Million USD | -66.27% |
| 2017 | 20.78 Million USD | 66.76% |
| 2016 | 12.46 Million USD | -16.73% |
| 2015 | 14.96 Million USD | 25.54% |
| 2014 | 11.92 Million USD | -70.43% |
| 2013 | 40.31 Million USD | 236.75% |
| 2012 | 11.97 Million USD | -61.62% |
| 2011 | 31.19 Million USD | 187.16% |
| 2010 | 10.86 Million USD | 20.46% |
| 2009 | 9.01 Million USD | -6.25% |
| 2008 | 9.61 Million USD | 36.2% |
| 2007 | 7.06 Million USD | -12.08% |
| 2006 | 8.03 Million USD | -30.57% |
| 2005 | 11.57 Million USD | -24.7% |
| 2004 | 15.36 Million USD | 108.07% |
| 2003 | 7.38 Million USD | 4.31% |
| 2002 | 7.07 Million USD | -37.51% |
| 2001 | 11.32 Million USD | 49.6% |
| 2000 | 7.57 Million USD | -26.64% |
| 1999 | 10.32 Million USD | -13.94% |
| 1998 | 11.99 Million USD | -71.15% |
| 1997 | 41.57 Million USD | -34.91% |
| 1996 | 63.87 Million USD | 165.03% |
| 1995 | 24.1 Million USD | 0.0% |
| 1994 | 24.1 Million USD | 91.27% |
| 1993 | 12.6 Million USD | -3.08% |
| 1992 | 13 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 5.69 Million USD | -30.67% |
| 2023 Q1 | 2.36 Million USD | -45.84% |
| 2023 Q2 | 8.21 Million USD | 247.18% |
| 2022 Q3 | 6.25 Million USD | 149.97% |
| 2022 Q2 | 2.5 Million USD | -30.49% |
| 2022 Q1 | 3.6 Million USD | -45.79% |
| 2022 FY | 4.37 Million USD | -34.21% |
| 2022 Q4 | 4.37 Million USD | -30.15% |
| 2021 Q1 | 10.07 Million USD | 29.89% |
| 2021 Q2 | 11.28 Million USD | 11.95% |
| 2021 Q3 | 8.95 Million USD | -20.58% |
| 2021 Q4 | 6.64 Million USD | -25.84% |
| 2021 FY | 6.64 Million USD | -14.35% |
| 2020 Q1 | 4.47 Million USD | 7.86% |
| 2020 Q3 | 5.99 Million USD | -15.63% |
| 2020 FY | 7.75 Million USD | 86.9% |
| 2020 Q4 | 7.75 Million USD | 29.39% |
| 2020 Q2 | 7.1 Million USD | 58.73% |
| 2019 Q3 | 4.82 Million USD | -40.7% |
| 2019 Q1 | 4.95 Million USD | -29.24% |
| 2019 Q2 | 8.13 Million USD | 63.93% |
| 2019 FY | 4.15 Million USD | -40.78% |
| 2019 Q4 | 4.15 Million USD | -13.91% |
| 2018 Q4 | 7 Million USD | -23.05% |
| 2018 FY | 7 Million USD | -66.27% |
| 2018 Q1 | 18.32 Million USD | -11.83% |
| 2018 Q2 | 8.66 Million USD | -52.73% |
| 2018 Q3 | 9.1 Million USD | 5.18% |
| 2017 Q2 | 25.9 Million USD | -21.33% |
| 2017 Q1 | 32.92 Million USD | 164.21% |
| 2017 Q4 | 20.78 Million USD | -8.07% |
| 2017 Q3 | 22.6 Million USD | -12.73% |
| 2017 FY | 20.78 Million USD | 66.76% |
| 2016 Q2 | 8.68 Million USD | -29.32% |
| 2016 Q1 | 12.28 Million USD | -17.91% |
| 2016 Q4 | 12.46 Million USD | 11.37% |
| 2016 Q3 | 11.18 Million USD | 28.88% |
| 2016 FY | 12.46 Million USD | -16.73% |
| 2015 Q4 | 14.96 Million USD | -14.41% |
| 2015 Q1 | 10.91 Million USD | -8.41% |
| 2015 FY | 14.96 Million USD | 25.54% |
| 2015 Q2 | 22.19 Million USD | 103.32% |
| 2015 Q3 | 17.48 Million USD | -21.24% |
| 2014 Q1 | 32.63 Million USD | -19.04% |
| 2014 FY | 11.92 Million USD | -70.43% |
| 2014 Q2 | 23.58 Million USD | -27.73% |
| 2014 Q4 | 11.92 Million USD | -32.43% |
| 2014 Q3 | 17.64 Million USD | -25.21% |
| 2013 Q2 | 31.11 Million USD | 128.73% |
| 2013 Q3 | 49.93 Million USD | 60.47% |
| 2013 FY | 40.31 Million USD | 236.75% |
| 2013 Q4 | 40.31 Million USD | -19.26% |
| 2013 Q1 | 13.6 Million USD | 13.64% |
| 2012 Q3 | 13.6 Million USD | -32.01% |
| 2012 Q1 | 24.72 Million USD | -20.73% |
| 2012 Q4 | 11.97 Million USD | -12.02% |
| 2012 FY | 11.97 Million USD | -61.62% |
| 2012 Q2 | 20.01 Million USD | -19.06% |
| 2011 Q2 | 11.98 Million USD | -13.6% |
| 2011 Q4 | 31.19 Million USD | -6.53% |
| 2011 FY | 31.19 Million USD | 187.16% |
| 2011 Q1 | 13.87 Million USD | 27.72% |
| 2011 Q3 | 33.37 Million USD | 178.39% |
| 2010 Q1 | 9.26 Million USD | 2.74% |
| 2010 FY | 10.86 Million USD | 20.46% |
| 2010 Q4 | 10.86 Million USD | 55.46% |
| 2010 Q3 | 6.98 Million USD | -11.46% |
| 2010 Q2 | 7.89 Million USD | -14.82% |
| 2009 FY | 9.01 Million USD | -6.25% |
| 2009 Q1 | 9.07 Million USD | -5.7% |
| 2009 Q4 | 9.01 Million USD | -2.14% |
| 2009 Q3 | 9.21 Million USD | 13.41% |
| 2009 Q2 | 8.12 Million USD | -10.42% |
| 2008 Q1 | 6.35 Million USD | -9.98% |
| 2008 Q4 | 9.61 Million USD | 30.89% |
| 2008 Q2 | 8.45 Million USD | 33.03% |
| 2008 FY | 9.61 Million USD | 36.2% |
| 2008 Q3 | 7.34 Million USD | -13.11% |
| 2007 Q4 | 7.06 Million USD | 16.7% |
| 2007 FY | 7.06 Million USD | -12.08% |
| 2007 Q1 | 6.85 Million USD | -14.73% |
| 2007 Q2 | 6.08 Million USD | -11.19% |
| 2007 Q3 | 6.05 Million USD | -0.52% |
| 2006 Q2 | 9.6 Million USD | -8.86% |
| 2006 Q1 | 10.54 Million USD | -8.91% |
| 2006 FY | 8.03 Million USD | -30.57% |
| 2006 Q4 | 8.03 Million USD | -2.9% |
| 2006 Q3 | 8.27 Million USD | -13.87% |
| 2005 Q2 | 13.67 Million USD | -7.07% |
| 2005 Q4 | 11.57 Million USD | -5.77% |
| 2005 FY | 11.57 Million USD | -24.7% |
| 2005 Q1 | 14.72 Million USD | -4.2% |
| 2005 Q3 | 12.27 Million USD | -10.24% |
| 2004 Q3 | 7.96 Million USD | -5.7% |
| 2004 FY | 15.36 Million USD | 108.07% |
| 2004 Q1 | 8.75 Million USD | 18.56% |
| 2004 Q2 | 8.44 Million USD | -3.58% |
| 2004 Q4 | 15.36 Million USD | 93.01% |
| 2003 FY | 7.38 Million USD | 4.31% |
| 2003 Q4 | 7.38 Million USD | 12.35% |
| 2003 Q3 | 6.57 Million USD | -4.42% |
| 2003 Q2 | 6.87 Million USD | 6.8% |
| 2003 Q1 | 6.43 Million USD | -9.05% |
| 2002 Q4 | 7.07 Million USD | -24.45% |
| 2002 Q1 | 9.94 Million USD | -12.24% |
| 2002 Q2 | 9.95 Million USD | 0.08% |
| 2002 Q3 | 9.37 Million USD | -5.83% |
| 2002 FY | 7.07 Million USD | -37.51% |
| 2001 Q4 | 11.32 Million USD | 45.24% |
| 2001 Q1 | 7.03 Million USD | -7.1% |
| 2001 FY | 11.32 Million USD | 49.6% |
| 2001 Q2 | 7.07 Million USD | 0.56% |
| 2001 Q3 | 7.8 Million USD | 10.26% |
| 2000 Q3 | 6.5 Million USD | -11.01% |
| 2000 Q1 | 6.59 Million USD | -36.09% |
| 2000 FY | 7.57 Million USD | -26.64% |
| 2000 Q4 | 7.57 Million USD | 16.46% |
| 2000 Q2 | 7.3 Million USD | 10.79% |
| 1999 Q1 | 12 Million USD | 0.05% |
| 1999 Q3 | 12.56 Million USD | 23.14% |
| 1999 Q4 | 10.32 Million USD | -17.83% |
| 1999 FY | 10.32 Million USD | -13.94% |
| 1999 Q2 | 10.2 Million USD | -15.0% |
| 1998 Q2 | 29.8 Million USD | -17.45% |
| 1998 FY | 11.99 Million USD | -71.15% |
| 1998 Q4 | 11.99 Million USD | -49.18% |
| 1998 Q1 | 36.1 Million USD | -13.17% |
| 1998 Q3 | 23.6 Million USD | -20.81% |
| 1997 Q2 | 52.9 Million USD | -8.0% |
| 1997 Q3 | 48.2 Million USD | -8.88% |
| 1997 Q4 | 41.57 Million USD | -13.75% |
| 1997 Q1 | 57.5 Million USD | -9.98% |
| 1997 FY | 41.57 Million USD | -34.91% |
| 1996 Q4 | 63.87 Million USD | 20.29% |
| 1996 Q1 | 23.2 Million USD | -3.73% |
| 1996 Q2 | 53.3 Million USD | 129.74% |
| 1996 Q3 | 53.1 Million USD | -0.38% |
| 1996 FY | 63.87 Million USD | 165.03% |
| 1995 Q2 | 18.3 Million USD | 66.36% |
| 1995 Q4 | 24.1 Million USD | 2.12% |
| 1995 Q1 | 11 Million USD | -54.36% |
| 1995 FY | 24.1 Million USD | 0.0% |
| 1995 Q3 | 23.6 Million USD | 28.96% |
| 1994 FY | 24.1 Million USD | 91.27% |
| 1994 Q3 | 10.2 Million USD | 20.0% |
| 1994 Q4 | 24.1 Million USD | 136.27% |
| 1994 Q2 | 8.5 Million USD | -22.02% |
| 1994 Q1 | 10.9 Million USD | -13.49% |
| 1993 Q4 | 12.6 Million USD | 51.81% |
| 1993 FY | 12.6 Million USD | -3.08% |
| 1993 Q1 | 11.6 Million USD | -10.77% |
| 1993 Q2 | 9.7 Million USD | -16.38% |
| 1993 Q3 | 8.3 Million USD | -14.43% |
| 1992 FY | 13 Million USD | 0.0% |
| 1992 Q3 | 5.4 Million USD | 0.0% |
| 1992 Q4 | 13 Million USD | 140.74% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 77.444% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 23.787% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 96.025% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 94.632% |
| Azitra, Inc. | 5.11 Million USD | 14.542% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | 56.236% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -4435.284% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | 56.367% |
| CEL-SCI Corporation | 30.52 Million USD | 85.68% |
| iBio, Inc. | 28.73 Million USD | 84.786% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 95.672% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | 42.227% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 93.334% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | 51.609% |
| NanoViricides, Inc. | 12.82 Million USD | 65.908% |
| Oragenics, Inc. | 4.96 Million USD | 11.975% |
| BiomX Inc. | 58.15 Million USD | 92.483% |
| BiomX Inc. | 58.15 Million USD | 92.483% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 94.822% |
| Palatin Technologies, Inc. | 10.74 Million USD | 59.305% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 91.435% |
| Theriva Biologics, Inc. | 60.21 Million USD | 92.74% |